Profil

Profil Institut für Stoffwechselforschung GmbH is a privately held, revenue-generating contract research organization (CRO) headquartered in Neuss, Germany. It has established itself as the global leader in conducting complex early clinical trials for diabetes and obesity therapeutics and medical devices, having contributed to the development of all major anti-diabetic drug classes. Its core business model is providing specialized clinical trial services to pharmaceutical and biotech sponsors, leveraging a deep scientific foundation and proprietary methodologies like the ClampArt® glucose clamp system. The company's success is evidenced by its long-term partnerships with industry giants such as Novo Nordisk, Eli Lilly, Sanofi, and Boehringer Ingelheim.

Integrated platform for metabolic clinical trials centered on the proprietary ClampArt® glucose clamp system, complemented by stable isotope techniques, tissue biopsies, pancreatic clamps, body composition analysis, vascular and retinal imaging, and a GMP pharmacy.

Profil occupies a unique niche as the world's leading specialist CRO for metabolic disease trials. It competes with the early-phase units of large, global CROs (e.g., IQVIA, Parexel) and other niche metabolic research sites, but its depth of expertise, integrated method platform, and historical track record provide a significant competitive moat.